(3R)-N-甲基噁戊环-3-胺盐酸 | 1292324-63-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 中文名称: (3R)-N-甲基噁戊环-3-胺盐酸
• 英文名称: (R)-N-methyltetrahydrofuran-3-amine hydrochloride
• 英文别名: (R)-N-methyltetrahydrofuran-3-amine；(3R)-N-methyloxolan-3-amine;hydrochloride
• CAS: 1292324-63-0
• 化学式: C₅H₁₁NO*ClH
• 分子量: 137.609
• InChiKey: FHFUVNKNOZMSJF-NUBCRITNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.42
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3R)-N-甲基噁戊环-3-胺盐酸 、 4-(4-(((6-methoxy-2-(2-methylimidazo[1,2-b][1,2,4]triazin-6-yl)benzofuran-4-yl)oxy)methyl)thiazol-2-yl)benzoic acid trifluoroacetic acid salt 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.33h， 以60.5%的产率得到(R)-4-(4-(((6-methoxy-2-(2-methylimidazo[1,2-b][1,2,4]triazin-6-yl)benzofuran-4-yl)oxy)methyl)thiazol-2-yl)-N-methyl-N-(tetrahydrofuran-3-yl)benzamide
  参考文献：
  名称：

  Imidazotriazine and imidazodiazine compounds

  摘要：

  本发明提供了式I的噻唑化合物，其中X、Y、Z、X1、X2、X3、X4、X5、R1、R2、R4、R5、R6、R7和W如本文所定义，或其立体异构体、互变异构体、药学上可接受的盐、前药、酯或溶剂化合物形式，其中所有变量均如本文所定义。这些化合物是血小板聚集抑制剂，因此可用作治疗或预防血栓栓塞性疾病的药物。

  公开号：

  US09598419B1

文献信息

• HETEROCYCLIC COMPOUND
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20160159773A1

  公开（公告）日：2016-06-09

  The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种用于预防或治疗自身免疫性疾病（例如牛皮癣、类风湿关节炎、炎症性肠病、干燥综合征、贝赫切特病、多发性硬化症、系统性红斑狼疮等）等的药剂，其具有优越的Tyk2抑制作用。 本发明涉及一种由下式表示的化合物 其中每个符号如规范中定义的，或其盐。
• [EN] HER2 MUTATION INHIBITORS<br/>[FR] INHIBITEURS DE MUTATION HER2
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2022003575A1

  公开（公告）日：2022-01-06

  This invention relates to compounds of Formula (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

  本发明涉及式(I)的化合物及其对映体，以及式(I)及其对映体的药用可接受盐，其中L1、L2、R1、R2、R3和n如本文所定义。本发明还涉及包括这些化合物和盐的药物组合物，以及利用这些化合物、盐和组合物治疗需要的受试者中的异常细胞生长，包括癌症的方法和用途。
• Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein
  申请人：Prelude Therapeutics Incorporated

  公开号：US11130769B2

  公开（公告）日：2021-09-28

  The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.

  本公开涉及式 I 的化合物 还描述了包含式 I 化合物的药物组合物及其使用和制备方法。
• SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN
  申请人：Prelude Therapeutics, Incorporated

  公开号：EP3877390A1

  公开（公告）日：2021-09-15
• Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein
  申请人：Prelude Therapeutics Incorporated

  公开号：US20200148705A1

  公开（公告）日：2020-05-14

  The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.